Comparison of posterior cellular bonegraft options for single-level lumbar spinal fusion: a randomized trial.

Spine JJun 12, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Glenn R Buttermann

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of six types of bone graft materials for single-level lumbar spinal fusion in 175 patients. The study found that iliac bone autograft (IBG) and bone morphogenic protein (BMP) had the highest fusion rates at 98% and 94%, respectively, while various allograft options showed lower rates. Overall, outcomes improved across all groups.

Key findings

  • Fusion rates were 98% for IBG, 94% for BMP, and 85% for BMA.
  • Allograft MSC options had fusion rates ranging from 50% to 67%.
  • All groups showed significant improvement in pain and disability scores postoperatively.
  • BMP was identified as the most expensive graft material.

Why it matters

Understanding the comparative effectiveness of different bone graft materials can guide clinicians in selecting options that optimize patient outcomes while considering cost and potential complications associated with graft harvesting.

Source

Published in Spine J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.